Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $9.6 million.

  • Dianthus Therapeutics' Other Non-Current Assets rose 3941.48% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 3941.48%. This contributed to the annual value of $9.6 million for FY2024, which is 734.40% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Other Non-Current Assets stood at $9.6 million for FY2024, which was up 734.40% from $1.2 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Other Non-Current Assets registered a high of $9.6 million during FY2024, and its lowest value of $121,000 during FY2022.
  • In the last 3 years, Dianthus Therapeutics' Other Non-Current Assets had a median value of $1.2 million in 2023 and averaged $3.6 million.
  • Data for Dianthus Therapeutics' Other Non-Current Assets shows a peak YoY spiked of 853.72% (in 2023) over the last 5 years.
  • Dianthus Therapeutics' Other Non-Current Assets (Yearly) stood at $121,000 in 2022, then soared by 853.72% to $1.2 million in 2023, then spiked by 734.40% to $9.6 million in 2024.